-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, AZIuj/EXnlv+1/ZWVLHLRYZaDKwmjXQWl8HSmXwpoTVASDm1tTEvhpDUsu62qcs6 Jt55B1cai6+Va3RoE5jZRQ== 0000891618-98-003541.txt : 19980803 0000891618-98-003541.hdr.sgml : 19980803 ACCESSION NUMBER: 0000891618-98-003541 CONFORMED SUBMISSION TYPE: S-3MEF PUBLIC DOCUMENT COUNT: 3 333-58829 FILED AS OF DATE: 19980730 EFFECTIVENESS DATE: 19980730 SROS: NASD FILER: COMPANY DATA: COMPANY CONFORMED NAME: COULTER PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000942416 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943219075 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: S-3MEF SEC ACT: SEC FILE NUMBER: 333-60273 FILM NUMBER: 98674763 BUSINESS ADDRESS: STREET 1: 550 CALIFORNIA AVE STE 200 CITY: PALO ALTO STATE: CA ZIP: 94306 BUSINESS PHONE: 4158427300 MAIL ADDRESS: STREET 1: 550 CALIFORNIA AVE STE 200 CITY: PALO ALTO STATE: CA ZIP: 94306 S-3MEF 1 FORM S-3 PURSUANT TO RULE 462(B) 1 AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON JULY 31, 1998 REGISTRATION NO. 333- ================================================================================ SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ------------------------ FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ------------------------ COULTER PHARMACEUTICAL, INC. (Exact name of registrant as specified in its charter) DELAWARE 2834 94-3219075 (State or other jursidiction of (Primary Standard Industrial (I.R.S. Employer incorporation or organization) Classification Code Number) Identification Number)
------------------------ 550 California Avenue, Suite 200 Palo Alto, California 94306-1440 (650) 842-7500 (Address, including zip code, and telephone number, including area code, of registrant's principal executive offices) ------------------------ Michael F. Bigham President and Chief Executive Officer Coulter Pharmaceutical, Inc. 550 California Avenue, Suite 200 Palo Alto, California 94306-1440 (650) 842-7300 (Name, address and telephone number of agent for service) ------------------------ Copies to: James C. Kitch, Esq. Alan K. Austin, Esq. John A. Dado, Esq. Elizabeth R. Flint, Esq. Cooley Godward LLP Wilson Sonsini Goodrich & Rosati Five Palo Alto Square Professional Corporation 3000 El Camino Real 650 Page Mill Road Palo Alto, California 94306 Palo Alto, California 94304
------------------------ Approximate date of proposed sale to the public: As soon as practicable after the effective date of this Registration Statement. ------------------------ If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. [X] 333-58829 ------------------------ CALCULATION OF REGISTRATION FEE
================================================================================================================================ Title of Securities Amount to be Proposed Maximum Offering Proposed Maximum Aggregate Amount of To be registered Registered (1) Price Per Share Offering Price Registration Fee - -------------------------------------------------------------------------------------------------------------------------------- Common Stock, $0.001 par value 460,000 $25.00 $11,500,000 $3,393 ================================================================================================================================
(1) Includes 60,000 shares of Common Stock issuable upon exercise of the Underwriters' over-allotment option. ================================================================================ 2 Explanatory Note This registration statement is being filed pursuant to Rule 462(b) and General Instruction IV of Form S-3. Incorporated by reference herein is, in its entirety, the Registration Statement on Form S-3 (File No. 333-58829) of Coulter Pharmaceutical, Inc., which was declared effective by the Securities and Exchange Commission on July 30, 1998. 2 3 SIGNATURES Pursuant to the requirements of the Securities Act of 1933, the Registrant has caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Palo Alto, County of Santa Clara, State of California, on the 30th day of July, 1998. COULTER PHARMACEUTICAL, INC. By: /s/ WILLIAM G. HARRIS ------------------------------------- William G. Harris Vice President and Chief Financial Officer (Principal Financial Officer)
Signature Title Date - --------------------------------------- ------------------------------------ ---------------- /s/ MICHAEL F. BIGHAM* President, Chief Executive Officer July 30, 1998 ------------------------------------- and Director (Principal Executive Michael F. Bigham Officer) /s/ WILLIAM G. HARRIS Vice President and Chief Financial July 30, 1998 ------------------------------------- Officer (Principal Financial and William G. Harris Accounting Officer) /s/ BRIAN G. ATWOOD* Director July 30, 1998 ------------------------------------- Brian G. Atwood /s/ DONALD L. LUCAS* Director July 30, 1998 ------------------------------------- Donald L. Lucas /s/ ROBERT MOMSEN* Director July 30, 1998 ------------------------------------- Robert Momsen /s/ ARNOLD ORONSKY* Director July 30, 1998 ------------------------------------- Arnold Oronsky /s/ SUE VAN* Director July 30, 1998 ------------------------------------- Sue Van /s/ GEORGE J. SELLA JR.* Director July 30, 1998 ------------------------------------- George J. Sella, Jr. /s/ JOSEPH R. COULTER, III* Director July 30, 1998 ------------------------------------- Joseph R. Coulter, III *By: /s/ WILLIAM G. HARRIS ---------------------------- William G. Harris Attorney-in-Fact
3 4 EXHIBIT INDEX
EXHIBIT NUMBER DESCRIPTION OF DOCUMENT - ------- --------------------------------------------------------------------- 5.1 Opinion of Cooley Godward LLP. 23.1 Consent of Ernst & Young LLP. 23.2 Consent of Cooley Godward LLP. Reference is made to Exhibit 5.1.
EX-5.1 2 OPINION OF COOLEY GODWARD LLP. 1 Exhibit 5.1 [COOLEY GODWARD LLP LETTERHEAD] July 31, 1998 Coulter Pharmaceutical, Inc. 550 California Avenue, Suite 200 Palo Alto, California 94306-1440 Ladies and Gentlemen: You have requested our opinion with respect to certain matters in connection with the filing by Coulter Pharmaceutical, Inc. (the "Company") of a Post-Effective Amendment, pursuant to Rule 462(b), to the Registration Statement on Form S-3 filed with the Securities and Exchange Commission on July 10, 1998, as amended (the "Registration Statement"). The Post-Effective Amendment covers the offering of up to Four Hundred Sixty Thousand (460,000) shares of the Company's Common Stock, $.001 par value (the "Shares"). In connection with this opinion, we have (i) examined the Registration Statement and related Prospectus, your Amended and Restated Certificate of Incorporation and Bylaws, as amended, and such other documents, records, certificates, memoranda and other instruments as in our judgment are necessary or appropriate to enable us to render the opinion expressed below, (ii) assumed that the Amended and Restated Certificate of Incorporation, as set forth in Exhibit 3.1 of the Registration Statement, shall have been duly approved and filed with the office of the Delaware Secretary of State, and (iii) assumed that the shares of Common Stock will be sold by the Underwriters at the price established by the Pricing Committee of the Board of Directors of the Company. We have assumed the genuineness and authenticity of all documents submitted to us as originals, the conformity to originals of all documents submitted to us as copies thereof, and the due execution and delivery of all documents where due execution and delivery are a requisite to the effectiveness thereof. On the basis of the foregoing, and in reliance thereon, we are of the opinion that the Shares, when sold and issued in accordance with the Registration Statement and related Prospectus, will be validly issued, fully paid, and nonassessable. We consent to the filing of this opinion as an exhibit to the Registration Statement. Very truly yours, COOLEY GODWARD LLP /s/ James C. Kitch - ------------------ James C. Kitch EX-23.1 3 CONSENT OF ERNST & YOUNG LLP. 1 EXHIBIT 23.1 CONSENT OF ERNST & YOUNG LLP, INDEPENDENT AUDITORS We consent to the reference to our firm under the captions "Selected Consolidated Financial Data" and "Experts" and to the use of our report dated January 26, 1998 with respect to the consolidated financial statements of Coulter Pharmaceutical, Inc. in the Registration Statement (Form S-3) and related Prospectus of Coulter Pharmaceutical, Inc. for the registration of 460,000 shares of its common stock. /s/ Ernst & Young LLP. Palo Alto, California July 30, 1998 -----END PRIVACY-ENHANCED MESSAGE-----